Select Page

Infinium Global Research has added a new report on Liver Fibrosis Drug Market. The report covers the analysis of global as well as regional markets of liver fibrosis drug. Moreover, the report gives insights into the factors that affect the global as well as regional performance of the market in the short run and in the long run.According to the report, the global liver fibrosis drug market is projected to grow at a CAGR of 10.7% over the forecast period of 2019-2025.

For More Details Get FREE Sample Pages of this Research Report@

Liver fibrosis drugs are used when there is the formation of excessive amounts of scar tissue in the organ due to repetitive or long-lasting injury or inflammation. Various types of chronic liver disease eventually cause fibrosis. These drugs are applicable to treat biliary fibrosis, parasitic infection fibrosis, metabolic fibrosis alcoholic fibrosis, viral hepatitis fibrosis, intoxication fibrosis, cardiogenic fibrosis, and alcoholic fibrosis. Hospitals and clinics are major users of liver fibrosis drugs.

Rising Prevalence of Liver Fibrosis and Liver Diseases Drives the Growth of the Liver Fibrosis Drug Market

The rising prevalence of liver fibrosis and liver diseases drives the growth of the liver fibrosis drug market. There are around 2 million deaths per year worldwide. In addition, the factors such as increasing government funding for treatment of liver fibrosis and liver diseases, growing geriatric population and increasing health awareness contribute to the growth of the liver fibrosis drug market. As per the World Health Organization, the world’s population over 60 years will be 22%. The increasing consumption of alcohol and unhealthy diet habits increases the cases of liver fibrosis that boosts the demand for liver fibrosis market. On the other hand, strict government regulations for drug approval and the risk of side effects from the use of these drugs restrains the growth of the liver fibrosis drug market. Moreover, research and development to innovate new drugs create numerously opportunities for the liver fibrosis drug market.

North America Holds a Larger Share in the Global Liver Fibrosis Drug Market

North America holds a larger share in the global liver fibrosis drug market. North America has an increasing number of patients with liver fibrosis contributing to the growth of the liver fibrosis drug market. Asia-Pacific region is anticipated to grow in the liver fibrosis drug market. In the Asia-Pacific region, there will be 1.3 billion people age above 60 years by 2050.

Liver Fibrosis Drug Market: Segmentation

The report on global liver fibrosis drug market covers segments such as drug class, and distribution channel. On the basis of drug class, the sub-markets include interferon (IFN) therapy, nucleoside analog, maloti lipid, and other drug classes. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.

Liver Fibrosis Drug Market: Competitive Landscape

The report provides profiles of the companies in the market such as Dicerna Pharmaceuticals, Inc., Pharmaxis Limited, Celgene Corporation, Dynavax Technologies Corporation, Mirum Pharmaceuticals, Gilead Sciences, Inc., Merck & Co., Inc., Johnson and Johnson, Novartis AG, and Other companies.

Browse Detailed TOC and Description of this Exclusive Report@

Reasons to Buy this Report:

  • Comprehensive analysis of global as well as regional markets of the Liver Fibrosis Drug.
  • Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
  • Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
  • Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.